Clarivate Plc (CLVT) Dividend History

Company News

• Global Artificial Intelligence in Drug Commercialization Market to Observe Stupendous Growth at a CAGR of ~24% by 2032 | DelveInsight

  The increasing prevalence of chronic diseases is driving the demand for advanced and effective treatments, highlighting the need for AI-powered drug commercialization. Pharmaceutical companies are leveraging AI for personalized medicine, improving drug development and market strategy. Rising partnerships between technology providers and pharmaceutical firms are accelerating AI adoption, strengthening data analytics, and optimizing commercialization efforts.

  GlobeNewswire Inc.

  Featured Companies: ICLR TMO TNXP
• Clarivate Partners With Libraries To Unveil AI Research Assistant, Boosting Academic Integrity And Discovery

  Clarivate has launched Primo Research Assistant, an AI-powered library tool that provides instant answers to research queries and visibility into reliable sources, aiming to enhance academic integrity and discovery.

  Benzinga
• Clarivate (CLVT) to Develop Unified Library Solution for Ohio - Zacks Investment Research

  Clarivate has partnered with OhioLINK and SearchOhio to integrate their INN-Reach platforms, creating a unified library solution for Ohio. This partnership will expand Clarivate's presence in the academic market, but the company also faces near-term challenges like macroeconomic headwinds and competitive pressure.

  Zacks Investment Research

  Featured Companies: IQV ORCL
• Critical Insights From Clarivate Analyst Ratings: What You Need To Know

  Clarivate (NYSE:CLVT) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 2 1 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 1 2 1 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $7.9, with a high estimate of $10.00 and a low estimate of $6.00. Highlighting a 13.19% decrease, the current average has fallen from the previous average price target of $9.10. Breaking Down Analyst Ratings: A Detailed Examination The standing of Clarivate among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target George Tong Goldman Sachs Lowers Buy $7.50 $8.50 Toni Kaplan Morgan Stanley Lowers Equal-Weight $8.00 $9.00 Manav Patnaik Barclays Lowers Underweight $6.00 $7.00 Ashish Sabadra RBC Capital Lowers Sector Perform $8.00 $10.00 Owen Lau Oppenheimer Lowers Outperform $10.00 $11.00 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Clarivate. This information provides a snapshot of ...Full story available on Benzinga.com

  Benzinga
• Compared to Estimates, Clarivate (CLVT) Q1 Earnings: A Look at Key Metrics

  While the top- and bottom-line numbers for Clarivate (CLVT) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

  Zacks Investment Research